|Awarded On||August 20, 2014|
|Title||Regulation of MDM2-Mediated Oncogenesis and Anti-Tumor Immunity by USP15|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Shao-Cong Sun|
|Cancer Sites||All Sites|
The immune system is vital for controlling tumor growth and progression, and it is now clear that boosting the anti-tumor immunity (or immunotherapy) is a promising strategy to treat different types of cancer. A more attractive approach is to combine the immunotherapy with chemotherapy or targeted therapies. Unfortunately, virtually all of the currently used chemotherapeutic regimens can cause immunosuppression due to killing of rapidly dividing immune cells. It is thus an important task to characterize the immunoregulatory functions of the currently explored drug targets and identify new ones whose inhibition both attenuates tumor growth and favors immune activation. This proposed research ...